King's College London

Research portal

Residual enhancing disease after surgery for glioblastoma: Evaluation of practice in the United Kingdom

Research output: Contribution to journalArticle

Ruichong Ma, Aswin Chari, Paul M. Brennan, Andrew Alalade, Ian Anderson, Anna Solth, Hani J. Marcus, Colin Watts, British Neurosurgical Trainee Research Collaborative, Angelos Kolias, Rohit Sinha, Kevin O'Neill, Fahid Rasul, Keyoumars Ashkan, Heidi Paine, Robert Corns, Michael Jenkinson, Neil Kitchen, Damian Holliman, Laurence Glancz & 16 more Ahmed Aly, Stuart Smith, Puneet Plaha, Edward Dyson, Sebastian Toescu, Nick Haliasos, Arnab Ghosh, Edward McKintosh, Olamide Rominiyi, David Jellinek, Mat Gallagher, Tim Jones, Victoria Wykes, Paul Grundy, Imran Haq, Howard Brydon

Original languageEnglish
Pages (from-to)74-81
Number of pages8
JournalNeuro-Oncology Practice
Volume5
Issue number2
Early online date27 Sep 2017
DOIs
Publication statusPublished - Jun 2018

King's Authors

Abstract

Background: A growing body of clinical data highlights the prognostic importance of achieving gross total resection (GTR) in patients with glioblastoma. The aim of this study was to determine nationwide practice and attitudes towards achieving GTR and dealing with residual enhancing disease. Methods: The study was in 2 parts: an electronic questionnaire sent to United Kingdom neuro-oncology surgeons to assess surgical practice followed by a 3-month prospective, multicenter observational study of current neurosurgical oncology practice. Results: Twenty-seven surgeons representing 22 neurosurgical units completed the questionnaire. Prospective data were collected for 113 patients from 15 neurosurgical units. GTR was deemed to be achieved at time of surgery in 82% (91/111) of cases, but in only 45% (36/80) on postoperative MRI. Residual enhancing disease was deemed operable in 16.3% (13/80) of cases, however, no patient underwent early repeat surgery for residual enhancing disease. The most commonly cited reason (38.5%, 5/13) was perceived lack of clinical benefit. Conclusion: There is a subset of patients for whom GTR is thought possible, but not achieved at surgery. For these patients, early repeat resection may improve overall survival. Further prospective surgical research is required to better define the prognostic implications of GTR for residual enhancing disease and examine the potential benefit of this early re-intervention.

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454